Search

Your search keyword '"Chávez, Julio"' showing total 507 results
Start Over Author "Chávez, Julio"
507 results on '"Chávez, Julio"'

2. A Multidisciplinary Approach to Managing BTK Inhibitor Toxicity in Lymphoma and Chronic Lymphocytic Leukemia

Author

Muñoz, Javier L., Chavez, Julio C., Sotomayor, Eduardo M., Barrientos, Jacqueline C., Castillo, Jorge J., Rezaei, Nima, Series Editor, Aguiar, Rodrigo, Editorial Board Member, Ahmed, Atif A., Editorial Board Member, Ambrosio, Maria R., Editorial Board Member, Artac, Mehmet, Editorial Board Member, Augustine, Tanya N., Editorial Board Member, Bambauer, Rolf, Editorial Board Member, Bhat, Ajaz Ahmad, Editorial Board Member, Bertolaccini, Luca, Editorial Board Member, Bianchini, Chiara, Editorial Board Member, Cavic, Milena, Editorial Board Member, Chakrabarti, Sakti, Editorial Board Member, Cho, William C. S., Editorial Board Member, Czarnecka, Anna M., Editorial Board Member, Domingues, Cátia, Editorial Board Member, Eşkazan, A. Emre, Editorial Board Member, Fares, Jawad, Editorial Board Member, Fonseca Alves, Carlos E., Editorial Board Member, Fru, Pascaline, Editorial Board Member, Da Gama Duarte, Jessica, Editorial Board Member, García, Mónica C., Editorial Board Member, Gener, Melissa A.H., Editorial Board Member, Estrada Guadarrama, José Antonio, Editorial Board Member, Hargadon, Kristian M., Editorial Board Member, Holvoet, Paul, Editorial Board Member, Jurisic, Vladimir, Editorial Board Member, Kabir, Yearul, Editorial Board Member, Katsila, Theodora, Editorial Board Member, Kleeff, Jorg, Editorial Board Member, Liang, Chao, Editorial Board Member, Tan, Mei Lan, Editorial Board Member, Li, Weijie, Editorial Board Member, Prado López, Sonia, Editorial Board Member, Macha, Muzafar A., Editorial Board Member, Malara, Natalia, Editorial Board Member, Orhan, Adile, Editorial Board Member, Prado-Garcia, Heriberto, Editorial Board Member, Pérez-Velázquez, Judith, Editorial Board Member, Rashed, Wafaa M., Editorial Board Member, Sanguedolce, Francesca, Editorial Board Member, Sorrentino, Rosalinda, Editorial Board Member, Shubina, Irina Zh., Editorial Board Member, de Araujo, Heloisa Sobreiro Selistre, Editorial Board Member, Torres-Suárez, Ana Isabel, Editorial Board Member, Włodarczyk, Jakub, Editorial Board Member, Yeong, Joe Poh Sheng, Editorial Board Member, Toscano, Marta A., Editorial Board Member, Wong, Tak-Wah, Editorial Board Member, Yin, Jun, Editorial Board Member, Yu, Bin, Editorial Board Member, and Hamdy, Nadia M., Editorial Board Member

Published
2024
Full Text
View/download PDF

5. Semantics between customers and providers: The relation between product descriptions, reviews, and customer satisfaction in E-commerce

Author

Rodriguez-Diaz, Carlos A., Jimenez, Sergio, Bejarano, Daniel, Bernal-Chávez, Julio A., and Gelbukh, Alexander

Subjects
Computer Science - Social and Information Networks
Abstract

In social commerce, users dialogue with each other on the topics related to the providers' products. However, the language customers use may vary from the language vendors use on their e-commerce websites and product descriptions. This situation can lead to possible misunderstandings in the social dialogue between customers, and incidental costs in the dialogue between customers and vendors. One possible reason for this difference is that words used by customers may have different meanings compared to those used by product description writers. We present a novel approach to measure this potential lexical-semantic gap for various e-commerce domains using an information-theoretical approach based on a large corpus of user reviews and product descriptions. Additionally, we use neural word embeddings to identify words with the highest semantic drift between reviews and descriptions as a tool to construct a ground truth for the task. We found that low levels of lexical-semantic gap are related to better customer satisfaction. Besides, this work is a step towards a better understanding of the effect of the use of language in e-commerce and social commerce. Potential applications of this technology could lead to better communication between customers and improvements in customer satisfaction, services, and revenue. Furthermore, this study opens up perspectives for applications in other domains with relationships beyond client-vendor, such as citizen-government and patient-healthcare system.

Published
2022

6. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation

Author

Epperla, Narendranath, Huang, Ying, Cashen, Amanda F., Vaughn, John L., Hanel, Walter, Badar, Talha, Barta, Stefan K., Caimi, Paolo F., Sethi, Tarsheen K., Reddy, Nishitha, Karmali, Reem, Bello, Celeste, Chavez, Julio C., Kothari, Shalin K., Hernandez-Ilizaliturri, Francisco J., Svoboda, Jakub, Lansigan, Frederick, Glenn, Martha J., Cohen, Jonathon B., Sorge, Caryn, Christian, Beth, Herrera, Alex F., Hamadani, Mehdi, Costa, Luciano J., and Xavier, Ana C.

Published
2024
Full Text
View/download PDF

8. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation

Author

Iqbal, Madiha, Kumar, Ambuj, Dreger, Peter, Chavez, Julio, Sauter, Craig S., Sureda, Anna M., Bachanova, Veronika, Maziarz, Richard T., Dreyling, Martin, Smith, Sonali M., Jacobson, Caron, Glass, Bertram, Casulo, Carla, Oluwole, Olalekan O., Montoto, Silvia, Advani, Ranjana, Cohen, Jonathon, Salles, Gilles, Hamad, Nada, Kuruvilla, John, Kahl, Brad S., Shadman, Mazyar, Kanate, Abraham S., Budde, Lihua Elizabeth, Kamdar, Manali, Flowers, Christopher, Hamadani, Mehdi, and Kharfan-Dabaja, Mohamed A.

Published
2024
Full Text
View/download PDF

9. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas

Author

Bhansali, Rahul S., Ellin, Fredrik, Relander, Thomas, Cao, Miao, Li, Wenrui, Long, Qi, Ganesan, Nivetha, Stuver, Robert, Horwitz, Steven M., Wudhikarn, Kitsada, Hwang, Steven R., Bennani, N. Nora, Chavez, Julio, Sokol, Lubomir, Saeed, Hayder, Duan, Frank, Porcu, Pierluigi, Pullarkat, Priyanka, Mehta-Shah, Neha, Zain, Jasmine M., Ruiz, Miguel, Brammer, Jonathan E., Prakash, Rishab, Iyer, Swaminathan P., Olszewski, Adam J., Major, Ajay, Riedell, Peter A., Smith, Sonali M., Goldin, Caroline, Haverkos, Bradley, Hu, Bei, Zhuang, Tony Z., Allen, Pamela B., Toama, Wael, Janakiram, Murali, Brooks, Taylor R., Jagadeesh, Deepa, Hariharan, Nisha, Goodman, Aaron M., Hartman, Gabrielle, Ghione, Paola, Fayyaz, Fatima, Rhodes, Joanna M., Chong, Elise A., Gerson, James N., Landsburg, Daniel J., Nasta, Sunita D., Schuster, Stephen J., Svoboda, Jakub, Jerkeman, Mats, and Barta, Stefan K.

Published
2024
Full Text
View/download PDF

10. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

Author

Bannerji, Rajat, Arnason, Jon E, Advani, Ranjana H, Brown, Jennifer R, Allan, John N, Ansell, Stephen M, Barnes, Jeffrey A, O'Brien, Susan M, Chávez, Julio C, Duell, Johannes, Rosenwald, Andreas, Crombie, Jennifer L, Ufkin, Melanie, Li, Jingjin, Zhu, Min, Ambati, Srikanth R, Chaudhry, Aafia, Lowy, Israel, and Topp, Max S

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Lymphoma, Cancer, Biotechnology, Clinical Research, Hematology, Immunization, Orphan Drug, Genetics, Rare Diseases, Immunotherapy, Health Disparities, Patient Safety, Lymphatic Research, Minority Health, Vaccine Related, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Aged, Antibodies, Bispecific, Antigens, CD20, Antineoplastic Agents, Cytokine Release Syndrome, Female, Humans, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Male, Middle Aged, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

BackgroundOdronextamab is a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells. We aimed to evaluate the safety and antitumour activity of odronextamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.MethodsThis single-arm, multicentre, phase 1, dose-escalation and dose-expansion (ELM-1) trial was conducted at ten academic sites across the USA and Germany. Patients aged 18 years or older with CD20-positive relapsed or refractory B-cell malignancies who previously received CD20-directed antibody therapy and who had at least one measurable lesion, and an ECOG performance status of 0 or 1 were included. Patients received intravenous odronextamab, according to a step-up dosing schedule in cycle 1, followed by treatment once per week at target doses ranging from 0·1 mg to 320 mg during cycles 2-4 (each cycle was 21 days). After cycle 4, maintenance treatment occurred every 2 weeks until disease progression or unacceptable toxicity. The primary endpoint of safety was assessed by the incidence of adverse events and dose-limiting toxicities to determine the maximum tolerated dose or phase 2 dose of odronextamab, or both. Preliminary antitumour activity, as measured by objective response rate, was a secondary endpoint. This study is registered with ClinicalTrials.gov, NCT02290951.FindingsFrom Feb 4, 2015, to Sept 25, 2021, 145 heavily pretreated patients (median of 3 (IQR 2-5] previous therapies) were enrolled (94 to the dose-escalation and 51 to the dose-expansion part of the study). The median age of patients was 67·0 years (IQR 57·0-73·0); 101 (70%) were male and 44 (30%) were female; most participants were White (119 [82%]) and not Hispanic or Latino (132 [91%]). 42 (29%) patients received previous CAR T therapy and 119 (82%) were refractory to the last line of therapy. Median duration of follow-up was 4·2 months (IQR 1·5-11·5). During dose escalation, odronextamab was administered up to the maximum dose of 320 mg once per week and no dose-limiting toxicities were observed. The recommended dose for expansion in patients with follicular lymphoma grade 1-3a was 80 mg and was 160 mg for patients with diffuse large B-cell lymphoma. Cytokine release syndrome and neurological treatment-emergent adverse events were predominantly low grade and did not result in treatment discontinuation. The most common grade 3 or worse treatment-emergent adverse events were anaemia (36 [25%]), lymphopenia (28 [19%]), hypophosphataemia (27 [19%]), neutropenia (27 [19%]), and thrombocytopenia (20 [14%]). Serious treatment-emergent adverse events occurred in 89 (61%) of 145 patients; the most frequent were cytokine release syndrome (41 [28%]), pyrexia (11 [8%]), pneumonia (nine [6%]), and infusion-related reaction (six [4%]). Four deaths were considered related to treatment (gastric perforation in a patient with gastric involvement by lymphoma, lung infection, pneumonia, and tumour-lysis syndrome). Objective response rate was 51% (95% CI 42-59; 72 of 142). In patients with follicular lymphoma who received odronextamab doses of 5 mg or higher, the objective response rate was 91% (95% CI 75-98; 29 of 32) and the complete response rate was 72% (95% CI 53-86; 23 of 32). In patients with diffuse large B-cell lymphoma without previous CAR T-cell therapy who received doses of 80 mg or higher, the objective response rate was 53% (eight of 15) and all responses were complete responses. In patients with diffuse large B-cell lymphoma who had previous CAR T-cell therapy and received doses of 80 mg or higher, the objective response rate was 33% (ten of 30) and complete response rate was 27% (eight of 30).InterpretationOdronextamab monotherapy showed a manageable safety profile and encouraging preliminary activity, including durable responses in heavily pretreated patients with B-cell non-Hodgkin lymphoma, supporting further clinical investigation in phase 2 and 3 trials.FundingRegeneron Pharmaceuticals.

Published
2022

11. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis

Author

Chavez, Julio C, Grajales, Ariel, Sandoval-Sus, Jose, Turba, Elyce, Nodzon, Lisa, Uriepero-Palma, Angimar, Ammad-Ud-Din, Mohammad, Sahakian, Eva, Komrokji, Rami, Sokol, Lubomir, Locke, Frederick L, Shah, Bijal, Lancet, Jeffrey, Sotomayor, Eduardo M, Kharfan-Dabaja, Mohamed A., Bello, Celeste, and Pinilla-Ibarz, Javier

Published
2024
Full Text
View/download PDF

12. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Author

Dreyling, Martin, Fowler, Nathan Hale, Dickinson, Michael, Martinez-Lopez, Joaquin, Kolstad, Arne, Butler, Jason, Ghosh, Monalisa, Popplewell, Leslie, Chavez, Julio C., Bachy, Emmanuel, Kato, Koji, Harigae, Hideo, Kersten, Marie José, Andreadis, Charalambos, Riedell, Peter A., Ho, P. Joy, Pérez-Simón, José Antonio, Chen, Andy I., Nastoupil, Loretta J., von Tresckow, Bastian, María Ferreri, Andrés José, Teshima, Takanori, Patten, Piers E. M., McGuirk, Joseph P., Petzer, Andreas L., Offner, Fritz, Viardot, Andreas, Zinzani, Pier Luigi, Malladi, Ram, Paule, Ines, Zia, Aiesha, Awasthi, Rakesh, Han, Xia, Germano, Davide, O’Donovan, Darragh, Ramos, Roberto, Maier, Harald J., Masood, Aisha, Thieblemont, Catherine, and Schuster, Stephen J.

Published
2024
Full Text
View/download PDF

13. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

Author

Jain, Michael D., Jacobs, Miriam T., Gao, Feng, Nastoupil, Loretta J., Spiegel, Jay Y., Lin, Yi, Dahiya, Saurabh, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick, Oluwole, Olalekan, McGuirk, Joseph, Deol, Abhinav, Sehgal, Alison R., Goy, Andre, Hill, Brian T., Andreadis, Charalambos, Munoz, Javier, Chavez, Julio C, Bennani, N. Nora, Rapoport, Aaron P., Vose, Julie M., Miklos, David, Neelapu, Sattva S., Locke, Frederick L., and Ghobadi, Armin

Published
2024
Full Text
View/download PDF

14. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Author

Neelapu, Sattva S., Chavez, Julio C., Sehgal, Alison R., Epperla, Narendranath, Ulrickson, Matthew, Bachy, Emmanuel, Munshi, Pashna N., Casulo, Carla, Maloney, David G., de Vos, Sven, Reshef, Ran, Leslie, Lori A., Oluwole, Olalekan O., Yakoub-Agha, Ibrahim, Khanal, Rashmi, Rosenblatt, Joseph, Korn, Ronald, Peng, Weixin, Lui, Christine, Wulff, Jacob, Shen, Rhine, Poddar, Soumya, Jung, A. Scott, Miao, Harry, Beygi, Sara, and Jacobson, Caron A.

Published
2024
Full Text
View/download PDF

15. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

Author

Gerson, James N., Handorf, Elizabeth, Villa, Diego, Gerrie, Alina S., Chapani, Parv, Li, Shaoying, Medeiros, L. Jeffrey, Wang, Michael, Cohen, Jonathon B., Churnetski, Michael, Hill, Brian T., Sawalha, Yazeed, Hernandez-Ilizaliturri, Francisco J., Kothari, Shalin, Vose, Julie M., Bast, Martin, Fenske, Timothy, Rao Gari, Swapna Narayana, Maddocks, Kami J., Bond, David, Bachanova, Veronika, Kolla, Bhaskar, Chavez, Julio, Shah, Bijal, Lansigan, Frederick, Burns, Timothy, Donovan, Alexandra M., Wagner-Johnston, Nina, Messmer, Marcus, Mehta, Amitkumar, Anderson, Jennifer K., Reddy, Nishitha, Kovach, Alexandra E., Landsburg, Daniel J., Glenn, Martha, Inwards, David J., Ristow, Kay, Karmali, Reem, Kaplan, Jason B., Caimi, Paolo F., Rajguru, Saurabh, Evens, Andrew, Klein, Andreas, Umyarova, Elvira, Pulluri, Bhargavi, Amengual, Jennifer E., Lue, Jennifer K., Diefenbach, Catherine, Fisher, Richard I., and Barta, Stefan K.

Published
2023
Full Text
View/download PDF

19. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Author

Neelapu, Sattva S., Jacobson, Caron A., Ghobadi, Armin, Miklos, David B., Lekakis, Lazaros J., Oluwole, Olalekan O., Lin, Yi, Braunschweig, Ira, Hill, Brian T., Timmerman, John M., Deol, Abhinav, Reagan, Patrick M., Stiff, Patrick, Flinn, Ian W., Farooq, Umar, Goy, Andre H., McSweeney, Peter A., Munoz, Javier, Siddiqi, Tanya, Chavez, Julio C., Herrera, Alex F., Bartlett, Nancy L., Bot, Adrian A., Shen, Rhine R., Dong, Jinghui, Singh, Kanwarjit, Miao, Harry, Kim, Jenny J., Zheng, Yan, and Locke, Frederick L.

Published
2023
Full Text
View/download PDF

20. Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell Therapy

Author

Hoogland, Aasha I., Barata, Anna, Li, Xiaoyin, Irizarry-Arroyo, Nathaly, Jain, Michael D., Welniak, Taylor, Rodriguez, Yvelise, Oswald, Laura B., Gudenkauf, Lisa M., Chavez, Julio C., Khimani, Farhad, Lazaryan, Aleksandr, Liu, Hien D., Nishihori, Taiga, Pinilla-Ibarz, Javier, Shah, Bijal D., Crowder, Sylvia L., Parker, Nathan H., Carson, Tiffany L., Vinci, Christine E., Pidala, Joseph A., Logue, Jennifer, Locke, Frederick L., and Jim, Heather S.L.

Published
2024
Full Text
View/download PDF

21. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Author

Elsawy, Mahmoud, Chavez, Julio C., Avivi, Irit, Larouche, Jean-François, Wannesson, Luciano, Cwynarski, Kate, Osman, Keren, Davison, Kelly, Rudzki, Jakob D., Dahiya, Saurabh, Dorritie, Kathleen, Jaglowski, Samantha, Radford, John, Morschhauser, Franck, Cunningham, David, Martin Garcia-Sancho, Alejandro, Tzachanis, Dimitrios, Ulrickson, Matthew L., Karmali, Reem, Kekre, Natasha, Thieblemont, Catherine, Enblad, Gunilla, Dreger, Peter, Malladi, Ram, Joshi, Namita, Wang, Wei-Jhih, Solem, Caitlyn T., Snider, Julia Thornton, Cheng, Paul, To, Christina, and Kersten, Marie José

Published
2022
Full Text
View/download PDF

22. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Author

Jacobs, Miriam T., Jain, Michael D., Gao, Feng, Nastoupil, Loretta J., Spiegel, Jay Y., Lin, Yi, Dahiya, Saurabh, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick M., Oluwole, Olalekan O., McGuirk, Joseph, Deol, Abhinav, Sehgal, Alison, Goy, Andre, Hill, Brian T., Andreadis, Charalambos, Munoz, Javier, Chavez, Julio C., Bennani, N. Nora, Rapoport, Aaron P., Vose, Julie M., Miklos, David B., Neelapu, Sattva S., Ghobadi, Armin, and Locke, Frederick L.

Published
2022
Full Text
View/download PDF

24. Community Training Institute for Health Disparities: Outcomes of a Formal Opportunity for Community Capacity Building to Increase Health Equity in Southern Puerto Rico.

Author

Jiménez-Chávez, Julio, Rosario-Maldonado, Fernando J., Vélez-Maldonado, David A., Rodríguez-Torruella, Dorimar, Aguirre-Hernández, Jeannie M., Castro-Figueroa, Eida, Asencio-Toro, Gloria, Rivera-Mateo, Elizabeth, Morales-Torres, Luisa, Ramos-Lucca, Axel, Motta-Pagán, Jorge L., Wallerstein, Nina, and Marzán-Rodríguez, Melissa

Published
2025
Full Text
View/download PDF

25. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma

Author

Zhang, Yumeng, Rose, Ashley, Khadka, Sushmita, Cao, Biwei, Eatrides, Jennifer, Saeed, Hayder, Shah, Bijal D., Chavez, Julio, Bello, Celeste, Lazaryan, Aleksandr, Khimani, Farhad, Ibarz, Javier Pinilla, Liu, Hien D., Locke, Frederick L., Jain, Michael D., Zhang, Ling, Kharfan-Dabaja, Mohamed A., Kim, Jongphil, Ayala, Ernesto, Nishihori, Taiga, and Sokol, Lubomir

Published
2024
Full Text
View/download PDF

27. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Author

Orellana-Noia, Victor Manuel, Reed, Daniel R., McCook, Ashley Alesia, Sen, Jeremy Michael, Barlow, Christian M., Malecek, Mary-Kate, Watkins, Marcus, Kahl, Brad S., Spinner, Michael A., Advani, Ranjana, Voorhees, Timothy J., Snow, Anson, Grover, Natalie Sophia, Ayers, Amy, Romancik, Jason, Liu, Yuxin, Huntington, Scott F., Chavez, Julio C., Saeed, Hayder, Lazaryan, Aleksandr, Raghunathan, Vikram, Spurgeon, Stephen E., Ollila, Thomas A., Del Prete, Christopher, Olszewski, Adam, Ayers, Emily C., Landsburg, Daniel J., Echalier, Benjamin, Lee, Jun, Kamdar, Manali, Caimi, Paolo F., Fu, Timothy, Liu, Jieqi, David, Kevin A., Alharthy, Hanan, Law, Jennie, Karmali, Reem, Shah, Harsh, Stephens, Deborah M., Major, Ajay, Rojek, Alexandra E., Smith, Sonali M., Yellala, Amulya, Kallam, Avyakta, Nakhoda, Shazi, Khan, Nadia, Sohail, Mohammad Ahsan, Hill, Brian T., Barrett-Campbell, Odeth, Lansigan, Frederick, Switchenko, Jeffrey, Cohen, Jonathon, and Portell, Craig A.

Published
2022
Full Text
View/download PDF

28. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Author

Jacobson, Caron A, Chavez, Julio C, Sehgal, Alison R, William, Basem M, Munoz, Javier, Salles, Gilles, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Yakoub-Agha, Ibrahim, Oluwole, Olalekan O, Fung, Henry Chi Hang, Rosenblatt, Joseph, Rossi, John M, Goyal, Lovely, Plaks, Vicki, Yang, Yin, Vezan, Remus, Avanzi, Mauro P, and Neelapu, Sattva S

Published
2022
Full Text
View/download PDF

30. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Author

Davids, Matthew S., O'Connor, Owen A., Jurczak, Wojciech, Samaniego, Felipe, Fenske, Timothy S., Zinzani, Pier Luigi, Patel, Manish R., Ghosh, Nilanjan, Cheson, Bruce D., Derenzini, Enrico, Brander, Danielle M., Reeves, James A., Knopińska-Posłuszny, Wanda, Allan, John N., Phillips, Tycel, Caimi, Paolo F., Lech-Maranda, Ewa, Burke, John M., Agajanian, Richy, Pettengell, Ruth, Leslie, Lori A., Cheah, Chan Y., Fonseca, Gustavo, Essell, James, Chavez, Julio C., Pagel, John M., Sharman, Jeff P., Hsu, Yanzhi, Miskin, Hari P., Sportelli, Peter, Weiss, Michael S., and Flinn, Ian W.

Published
2021
Full Text
View/download PDF

31. Role of calcium oscillations in sperm physiology

Author

Mata-Martínez, Esperanza, Sánchez-Cárdenas, Claudia, Chávez, Julio C., Guerrero, Adán, Treviño, Claudia L., Corkidi, Gabriel, Montoya, Fernando, Hernandez-Herrera, Paul, Buffone, Mariano G., Balestrini, Paula A., and Darszon, Alberto

Published
2021
Full Text
View/download PDF

32. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Author

Jain, Michael D., Zhao, Hua, Wang, Xuefeng, Atkins, Reginald, Menges, Meghan, Reid, Kayla, Spitler, Kristen, Faramand, Rawan, Bachmeier, Christina, Dean, Erin A., Cao, Biwei, Chavez, Julio C., Shah, Bijal, Lazaryan, Aleksandr, Nishihori, Taiga, Hussaini, Mohammed, Gonzalez, Ricardo J., Mullinax, John E., Rodriguez, Paulo C., Conejo-Garcia, Jose R., Anasetti, Claudio, Davila, Marco L., and Locke, Frederick L.

Published
2021
Full Text
View/download PDF

34. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma

Author

Merryman, Reid W., Redd, Robert A., Nishihori, Taiga, Chavez, Julio, Nieto, Yago, Darrah, Justin M., Rao, Uttam, Byrne, Michael T., Bond, David A., Maddocks, Kami J., Spinner, Michael A., Advani, Ranjana H., Ballard, Hatcher J., Svoboda, Jakub, Singh, Anurag K., McGuirk, Joseph P., Modi, Dipenkumar, Ramchandren, Radhakrishnan, Romancik, Jason, Cohen, Jonathon B., Frigault, Matthew J., Chen, Yi-Bin, Serritella, Anthony V., Kline, Justine, Ansell, Stephen, Nathan, Sunita, Rahimian, Maryam, Joyce, Robin M., Shah, Mansi, David, Kevin A., Park, Steven, Beaven, Anne W., Habib, Alma, Bachanova, Veronika, Nakhoda, Shazia, Khan, Nadia, Lynch, Ryan C., Smith, Stephen D., Ho, Vincent T., LaCasce, Ann, Armand, Philippe, and Herrera, Alex F.

Published
2021
Full Text
View/download PDF

37. Motricidad Infantil

Author

Vallejo Zambrano, Cristhian Rubén, primary, Pico Tejena, Karen Mariuxi, additional, Becerra Ávila, María Ivonne, additional, Rodríguez Ortiz, Vanessa Priscila, additional, Mera Cedeño, Johana Pilar, additional, Mieles Álava, Génesis, additional, Beltrán Cevallos, Andrés Medardo, additional, Flores Chávez, Julio Eduardo, additional, Macías Valle, Kiara Belén, additional, and Chancay López, Arantxa Magdalena, additional

Published
2022
Full Text
View/download PDF

47. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study

Author

Castillo, Jorge J., Itchaki, Gilad, Paludo, Jonas, Varettoni, Marzia, Buske, Christian, Eyre, Toby A., Chavez, Julio C., Shain, Kenneth H., Issa, Samar, Palomba, M. Lia, Pasvolsky, Oren, Simpson, David, Talaulikar, Dipti, Tam, Constantine S., Tedeschi, Alessandra, Ansell, Stephen M., Nayak, Lakshmi, and Treon, Steven P.

Published
2019
Full Text
View/download PDF

48. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Author

Locke, Frederick L, Ghobadi, Armin, Jacobson, Caron A, Miklos, David B, Lekakis, Lazaros J, Oluwole, Olalekan O, Lin, Yi, Braunschweig, Ira, Hill, Brian T, Timmerman, John M, Deol, Abhinav, Reagan, Patrick M, Stiff, Patrick, Flinn, Ian W, Farooq, Umar, Goy, Andre, McSweeney, Peter A, Munoz, Javier, Siddiqi, Tanya, Chavez, Julio C, Herrera, Alex F, Bartlett, Nancy L, Wiezorek, Jeffrey S, Navale, Lynn, Xue, Allen, Jiang, Yizhou, Bot, Adrian, Rossi, John M, Kim, Jenny J, Go, William Y, and Neelapu, Sattva S

Published
2019
Full Text
View/download PDF

49. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis

Author

Wood, Anthony C., Perez, Ariel Perez, Arciola, Brian, Patel, Kedar, Johnson, Grace, DiMaggio, Elizabeth, Bachmeier, Christina A., Reid, Kayla, Carallo, Salvatore, Vargas, Melanie H., Faramand, Rawan, Chavez, Julio C., Shah, Bijal, Gaballa, Sameh, Khimani, Farhad, Elmariah, Hany, Nishihori, Taiga, Lazaryan, Aleksandr, Freeman, Ciara, Davila, Marco L., Locke, Frederick L., Mhaskar, Rahul, Bassil, Claude, and Jain, Michael D.

Published
2022
Full Text
View/download PDF

50. ABCL-455 Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas

Author

Orellana-Noia, Victor, Reed, Daniel, McCook, Ashley, Sen, Jeremy, Barlow, Christian, Malecek, Mary-Kate, Watkins, Marcus, Kahl, Brad, Spinner, Michael, Advani, Ranjana, Voorhees, Timothy, Snow, Anson, Grover, Natalie, Ayers, Amy, Romancik, Jason, Liu, Yuxin, Huntington, Scott, Chavez, Julio, Saeed, Hayder, Lazaryan, Aleksandr, Raghunathan, Vikram, Spurgeon, Stephen, Ollila, Thomas, Prete, Christopher Del, Olszewski, Adam, Ayers, Emily, Landsburg, Daniel, Echalier, Benjamin, Lee, Jun, Kamdar, Manali, Calmi, Paolo, Fu, Timothy, Liu, Jieqi, David, Kevin, Alharthy, Hanan, Law, Jennie, Karmali, Reem, Shah, Harsh, Stephens, Deborah, Major, Ajay, Rojek, Alexandra, Smith, Sonali, Yellala, Amulya, Kallam, Ayvakta, Nakhoda, Shazia, Khan, Nadia, Sohail, Mohammad, Hill, Brian, Barrett-Campbell, Odeth, Lansigan, Frederick, Switchenko, Jeffrey, Cohen, Jonathon, and Portell, Craig

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results